Overview
Conference: October 24-25, 2024
In a market that is constantly adapting and adjusting to the needs of the healthcare field, real-world evidence (RWE) is becoming increasingly important for regulatory and reimbursement decision-making. Historically used for post-market safety monitoring, RWE is now integrated throughout the product development lifecycle, and has led to the real-time analysis of data to better understand and gain insights on disease, approaches to treatment, and how to substantiate coverage decisions.
DIA’s Real-World Evidence Conference will explore new, innovative applications of RWE, and deliver cutting-edge insights to leverage this knowledge to advance healthcare decision-making.
While we develop our 2024 agenda, please take a moment to review the last year final agenda
Participant Testimonials
DIA RWE is the best RWE-related event I've attended - it has compelling speakers, strong education opportunities, and a great collective of attendees. – Nicholaas Honig, JD, Senior Regulatory Counsel, Aetion
Great meeting. Very strong content. Was a really efficient way for me to catch up on RWD/E happenings over the past year! – Meredith Zozus, PhD, Professor; Division Chief and Director, Clinical Research Informatics, University of Texas Health Science Center
Program Committee
-
David Martin, MD, MPH Vice President, Global Head RWE
Moderna, United States -
Jaclyn Bosco, PhD, MPH, FISPE Vice President and Global Head of Epidemiology
IQVIA, United States -
John Concato, MD, MPH, MS Associate Director for Real-World Evidence Analytics, OMP, CDER
FDA, United States -
Diane Gubernot, DrPH, MPH Epidemiologist
US FDA, United States -
Rachele Hendricks-Sturrup, DrSc, MA, MSc Research Director, Real-World Evidence
Duke-Robert J. Margolis, MD, Center for Health Policy, United States -
Camille Jackson Director, Regulatory Policy; Legal and Regulatory
Flatiron Health , United States -
Charles Lee, MBA, MS Executive Regulatory Science Director
AstraZeneca, United States -
Alexander Liede, PhD, MSc Senior Director, Global Epidemiology
Abbvie, Ireland -
Sarah Martin, PhD, MS Senior Director - Global Regulatory Policy (Oncology)
Eli Lilly & Co., United States -
Brittany McKelvey, PhD Director, Regualtory Affairs
Friends of Cancer Research, United States -
Keri Monda, PhD, MS Executive Director, Center for Observational Research
Amgen, United States
Have an account?